- Home
- VRNA
VRNA
Verona Pharma plc
as 05-15-2025 4:00pm EST
| Founded: | 2005 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | N/A | IPO Year: | 2017 |
| Target Price: | $77.80 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.39 - $74.18 | Next Earning Date: | 04-29-2025 |
| Revenue: | $118,535,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 819.01% | Revenue Growth (next year): | 74.35% |
Stock Insider Trading Activity of Verona Pharma plc (VRNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rickard Kathleen A. | VRNA | Chief Medical Officer | May 6 '25 | Sell | $8.82 | 114,984 | $1,014,342.85 | 2,546,472 | |
| Hahn Mark W | VRNA | Chief Financial Officer | May 1 '25 | Sell | $9.00 | 587,008 | $5,311,479.00 | 13,478,992 | |
| Sinha Vikas | VRNA | Director | Apr 29 '25 | Sell | $8.92 | 20,000 | $178,416.00 | 74,440 | |
| Fisher Andrew | VRNA | General Counsel | Mar 19 '25 | Sell | $8.98 | 26,072 | $234,126.56 | 359,993 | |
| Rickard Kathleen A. | VRNA | Chief Medical Officer | Mar 12 '25 | Sell | $8.35 | 79,264 | $661,941.59 | 2,546,472 |
Latest Verona Pharma plc News
VRNA Breaking Stock News: Dive into VRNA Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Why Verona Pharma plc (VRNA) is Among the Best Performing Healthcare Stocks to Buy Now
Insider Monkey
7 days ago
What Makes Verona Pharma plc (VRNA) a Good Investment?
Investor's Business Daily
9 days ago
IBD Stock Of The Day Verona Pharma Tests Buy Point After Earnings Breakout
GlobeNewswire
10 days ago
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
MT Newswires
14 days ago
Verona Pharma Insider Sold Shares Worth $811,433, According to a Recent SEC Filing
Insider Monkey
15 days ago
Why Verona Pharma plc (VRNA) Soared on Tuesday
Simply Wall St.
16 days ago
Analysts Are Betting On Verona Pharma plc (NASDAQ:VRNA) With A Big Upgrade This Week
GuruFocus.com
16 days ago
Verona Pharma PLC (VRNA) Q1 2025 Earnings Call Highlights: Strong Ohtuvayre Sales Propel ...
Compare VRNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRNA Verona Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.